{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-005497","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-07-14T11:45:15+00:00","discovered_at":"2026-07-14T11:50:00.330724+00:00","generated_at":"2026-07-14T11:50:06.451052+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Valion Bio advances Entolimod platform with government engagement, 200x manufacturing scale-up, oncology expansion","bullets":["Continued discussions with BARDA, NIAID, AFRRI, and U.S. Department of War for ARS preparedness and stockpile opportunities.","Ukraine's Ministry of Health evaluating Entolimod for potential inclusion in national strategic reserves; no agreement yet.","Demonstrated 200-fold manufacturing scale-up via Velocity Bioworks, producing ~1.3M potential human doses at 50L fermentation scale.","Planning physician-sponsored studies of Entolimod in neutropenia; advancing next-gen TLR5 agonist Entolasta for oncology supportive care.","Over $140M invested in Entolimod development to date; company building integrated platform across biodefense, manufacturing, and oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-005497","json":"https://secwatch.observer/filing/0001683168-26-005497.json","markdown":"https://secwatch.observer/filing/0001683168-26-005497.md","text":"https://secwatch.observer/filing/0001683168-26-005497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/0001683168-26-005497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/valion_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T11:50:06.451052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}